Rational design of irreversible, pseudo-C2-symmetric hiv-1 protease inhibitors
Authors:
- Chihyo ParkCPChihyo Park
- Jong Sung KohJKJong Sung Koh
- Young Chan SonYSYoung Chan Son
- Ho-Il ChoiHCHo-Il Choi
- Chang Sun LeeCLChang Sun Lee
- Nakyen ChoyNCNakyen Choy
- Kwang Yul MoonKMKwang Yul Moon
- Won Hee JungWJWon Hee Jung
- Sung Chun KimSKSung Chun Kim
- Heungsik YoonHYHeungsik Yoon
- 1 August 1995
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 5 (16) , 1843-1848
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The HIV-1 Protease as a Therapeutic Target for AIDSAIDS Research and Human Retroviruses, 1992
- HIV protease: a novel chemotherapeutic target for AIDSJournal of Medicinal Chemistry, 1991
- Generation and characterization of the human immunodeficiency virus type 1 mutantsArchives of Virology, 1991
- Structure-based, C2 symmetric inhibitors of HIV proteaseJournal of Medicinal Chemistry, 1990
- Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analoguesNature, 1990
- Viral proteinases: weakness in strengthBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1990
- Conserved Folding in Retroviral Proteases: Crystal Structure of Synthetic HIV-1 ProteaseScience, 1989
- Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease.Proceedings of the National Academy of Sciences, 1989
- Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1Nature, 1989
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988